Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03717883 · ClinicalTrials.gov registry record
ADPKD Alterations in Hepatic Transporter Function
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 24
- Enrollment target
NCT03717883 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 24 participants.
The verdict
NCT03717883 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
This is a single center, comparative cohort study to investigate alterations in hepatic transporter function in subjects with autosomal dominant polycystic kidney disease (ADPKD) compared to healthy subjects and subjects with non-ADPKD renal disease. Eligible subjects will be 18-65 years of age and of any race/ethnicity and gender.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2020-01-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03717883
The ClinicalTrials.gov registry entry for NCT03717883 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03717883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03717883 about?
NCT03717883 is a clinical study titled "ADPKD Alterations in Hepatic Transporter Function". This is a single center, comparative cohort study to investigate alterations in hepatic transporter function in subjects with autosomal dominant polycystic kidney disease (ADPKD) compared to healthy subjects and subjects with non-ADPKD renal disease. Eligible subjects will be 18-65 years of age and ...
What is the current status of trial NCT03717883?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2018-09-17. Estimated completion is 2020-01-29.
Who is sponsoring clinical trial NCT03717883?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.